Kantar Health Blog

  • User Not Found
    This environment highlighted the need for clinical data asking whether continued VEGF inhibition would provide survival benefit to patients, and are addressed by two trials at ASCO 2012: TML (Treatment across Multiple Lines; ML18147) which examined the efficacy of Avastin and chemotherapy following first-line Avastin and chemotherapy. ASCO 2012
    Continue Reading > | Go comment! | Share
  • Natalie Bush
    T-DM1 is designed to take advantage of the targeted nature of the antibody to selectively deliver the cytotoxic agent to HER2+ breast cancer cells. Roche is hoping that T-DM1 will further expand their franchise in HER2+ breast cancer. Roche’s other product, Herceptin (trastuzumab), currently dominates the HER2+ market, with about 70% utilization in front-line HER2+ metastatic breast cancer patients. ASCO 2012
    Continue Reading > | Go comment! | Share
  • Renal Cell Carcinoma: How to Stand Out in a Crowd

    by User Not Found | Jun 2, 2012
    User Not Found
    There are currently 7 agents (excluding cytokines) approved for use in renal cell carcinoma (RCC), 5 of which are approved for use in the first-line setting, of which 4 are VEGF pathway inhibitors. With so many options, and few definitively differentiating factors, how is a physician (or patient) to choose the best course of therapy?
    Continue Reading > | Go comment! | Share
  • How will ASCO 2012 change the future of cancer?

    by User Not Found | May 7, 2012
    User Not Found
    Perhaps the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting could be the “Year of Many Cancers.” This blog highlights nine key Phase III trials that are known to or strongly believed to have hit their primary endpoints. (Zytiga, Tivozanib, Avastin, T-DM1, Dabrafenib, Trametinib, Cabozantinib, Afatinib)
    Continue Reading > | Go comment! | Share
  • User Not Found
    Unmet needs often drive innovation in oncology, as shown by the success of two paradigm-changing drugs for metastatic melanoma: Yervoy and Zelboraf. By having an active drug in an underserved, potentially biomarker-defined population like endometrial cancer, these developers will enjoy rapid uptake and a premium pricing.
    Continue Reading > | Go comment! | Share
Page